Kirby McInerney LLP is investigating potential claims against the Board of Directors of Auspex Pharmaceuticals, Inc. (“Auspex” or the “Company”) (NASDAQ:ASPX) concerning the proposed acquisition of the Company by Teva Pharmaceutical Industries Ltd. (“Teva”) (NYSE: TEVA). Under the terms of the definitive merger agreement, Auspex stockholders will receive $101 in cash for each share of Auspex common stock they own, valuing the transaction at approximately $3.2 billion.

The investigation concerns whether the Auspex Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values the Company’s common stock.

If you are an Auspex stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, or telephone at (212) 699-1145, Melissa Fortunato, Esq. by email at mfortunato@kmllp.com, or telephone at (212) 699-1141, or toll free at (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.